RU2016133587A - Системы и способы для идентификации злокачественных новообразований, имеющих активированные рецепторы прогестерона - Google Patents

Системы и способы для идентификации злокачественных новообразований, имеющих активированные рецепторы прогестерона Download PDF

Info

Publication number
RU2016133587A
RU2016133587A RU2016133587A RU2016133587A RU2016133587A RU 2016133587 A RU2016133587 A RU 2016133587A RU 2016133587 A RU2016133587 A RU 2016133587A RU 2016133587 A RU2016133587 A RU 2016133587A RU 2016133587 A RU2016133587 A RU 2016133587A
Authority
RU
Russia
Prior art keywords
nucleic acid
group
detecting
tissue sample
progesterone receptor
Prior art date
Application number
RU2016133587A
Other languages
English (en)
Inventor
Кристин Л. КЛАРК
Дж. Динни ГРЭХЭМ
Original Assignee
Дзе Юниверсити Оф Сидней
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Юниверсити Оф Сидней filed Critical Дзе Юниверсити Оф Сидней
Publication of RU2016133587A publication Critical patent/RU2016133587A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (25)

1. Способ лечения пациента с использованием антипрогестина, включающий в себя:
получение образца ткани, подозреваемой на туморогенность или злокачественность, от пациента;
обнаружение геномной ДНК, ассоциированной с прогестероновым рецептором в образце ткани;
обнаружение первого уровня транскрипции одной или нескольких ДНК-мишеней, ассоциированных с прогестероновым рецептором, в образце ткани, где ДНК-мишени выбирают из группы, состоящей из T47D2822, T47D299, T47D3514, T47D4414, T47D4818, T47D5045 и T47D5516;
обнаружение второго уровня транскрипции одной или нескольких ДНК-мишеней, ассоциированных с прогестероновым рецептором, в образце ткани с отрицательным контролем, где ДНК-мишени выбирают из группы, состоящей из T47D2822, T47D299, T47D3514, T47D4414, T47D4818, T47D5045 и T47D5516;
сравнение первого и второго уровней транскрипции; и
введение антипрогестина пациенту если уровень транскрипции одной или нескольких ДНК-мишеней, ассоциированных с прогестероновым рецептором, составляет, по меньшей мере, приблизительно в 4 раза выше, чем уровень в образце с отрицательным контролем.
2. Способ по п. 1, где образец ткани выбирают из группы, состоящей из менингиом молочной железы, мозга, сарком простаты, яичника, эндометрия, матки, лейомиомы матки и ткани легкого.
3. Способ по п. 1, где антипрогестин выбирают из группы, состоящей из онапристона, лонаприсана, мифепристона, PF-02413873, телапристона, лилопристона, ORG2058, апоприснила, улипристала, ZM172406, ZM150271, ZM172405 и аглепристона.
4. Способ по п. 1, где антипрогестин вводят пациенту в количестве от приблизительно 10 мг до приблизительно 200 мг в день.
5. Способ по п. 1, дополнительно включающий в себя введение противоопухолевого соединения.
6. Способ по п. 5, где противоопухолевое соединение выбирают из группы, состоящей из эверолимуса, трастузумаб, TM1-D, лекарственных средств против HER2, бевацизумаб, паклитаксела, доцетаксела, таксанов, доксорубицина, липосомального доксорубицина, пегилированного липосомального доксорубицина, антрациклинов, антрацендионов, карбоплатина, цисплатина, 5-ФУ, гемцитабина, циклофосфамида, антиэстрогена, селективных модуляторов эстрогенного рецептора, ингибиторов ароматазы и антиандрогенов.
7. Способ по п. 1, дополнительно включающий в себя обнаружение присутствия мотива связывания кофактора.
8. Способ по п. 7, где мотив связывания кофактора представляет собой FOXA1.
9. Способ по п. 1, где геномную ДНК обнаруживают посредством иммунопреципитации.
10. Способ по п. 9, где иммунопреципитацию проводят, используя моноклональные антитела hPRa6 и hPRa7.
11. Способ по п. 1, где прогестероновый рецептор, ассоциированный с геномной ДНК, обнаруживают посредством иммунопреципитации с первичным антителом против PR.
12. Изолированная по существу нуклеиновая кислота, содержащая нуклеиновую кислоту, выбранную из группы, состоящей из T47D2822, T47D299, T47D3514, T47D4414, T47D4818, T47D5045 и T47D5516.
13. Нуклеиновая кислота по п. 12, где нуклеиновая кислота представляет собой ДНК.
14. Нуклеиновая кислота по п. 12, где нуклеиновая кислота представляет собой РНК.
15. Изолированная по существу нуклеиновая кислота, содержащая нуклеиновую кислоту, комплементарную нуклеиновой кислоте, выбранной из группы, состоящей из T47D2822, T47D299, T47D3514, T47D4414, T47D4818, T47D5045 и T47D5516.
16. Нуклеиновая кислота по п. 15, где нуклеиновая кислота представляет собой ДНК.
17. Нуклеиновая кислота по п. 15, где нуклеиновая кислота представляет собой РНК.
18. Набор, содержащий нуклеиновую кислоту по п. 12, и моноклональные антитела для обнаружения присутствия геномных ДНК-мишеней.
19. Набор по п. 18, в котором моноклональные антитела представляют собой hPRa6 и hPRa7.
RU2016133587A 2014-03-12 2015-03-12 Системы и способы для идентификации злокачественных новообразований, имеющих активированные рецепторы прогестерона RU2016133587A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951650P 2014-03-12 2014-03-12
US61/951,650 2014-03-12
PCT/IB2015/000312 WO2015136355A1 (en) 2014-03-12 2015-03-12 Systems and methods for identifying cancers having activated progesterone receptors

Publications (1)

Publication Number Publication Date
RU2016133587A true RU2016133587A (ru) 2018-04-13

Family

ID=54070997

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016133587A RU2016133587A (ru) 2014-03-12 2015-03-12 Системы и способы для идентификации злокачественных новообразований, имеющих активированные рецепторы прогестерона

Country Status (8)

Country Link
US (1) US20150276767A1 (ru)
EP (1) EP3117013A1 (ru)
JP (1) JP2017510557A (ru)
CN (1) CN106460038A (ru)
AU (1) AU2015228524A1 (ru)
CA (1) CA2939861A1 (ru)
RU (1) RU2016133587A (ru)
WO (1) WO2015136355A1 (ru)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007078599A2 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
CA2822462A1 (en) * 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
RU2014147625A (ru) * 2012-04-27 2016-06-20 Реджентс Оф Зэ Юниверсити Оф Миннесота Прогнозирование рака молочной железы, предсказание подтипа прогестероновых рецепторов и предсказание ответа на лечение антипрогестином на основании генной экспрессии
US20140363425A1 (en) * 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors

Also Published As

Publication number Publication date
WO2015136355A1 (en) 2015-09-17
CN106460038A (zh) 2017-02-22
CA2939861A1 (en) 2015-09-17
EP3117013A1 (en) 2017-01-18
US20150276767A1 (en) 2015-10-01
JP2017510557A (ja) 2017-04-13
AU2015228524A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
Tang et al. Classification, treatment strategy, and associated drug resistance in breast cancer
Xu et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell
Chan et al. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology/gynecologic oncology group study (GOG-254)
Toft et al. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies
Massari et al. Emerging concepts on drug resistance in bladder cancer: Implications for future strategies
Cid et al. Advanced HER2-positive gastric cancer: current and future targeted therapies
Zanardi et al. Better together: targeted combination therapies in breast cancer
Teplinsky et al. Targeting HER2 in ovarian and uterine cancers: challenges and future directions
Wuerkenbieke et al. miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation
RU2014110504A (ru) Способы и системы для выявления и лечения опухолей, восприимчивых к антипрогестинам
Volk-Draper et al. Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy
Lim et al. Pushing estrogen receptor around in breast cancer
Liu et al. Toll-like receptor 2 stimulation promotes colorectal cancer cell growth via PI3K/Akt and NF-κB signaling pathways
Huang et al. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma
US20110142848A1 (en) Anti-beta-2-microglobulin agents and the use thereof
Lin et al. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells
Wang et al. MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1α feedback loop.
Bonello et al. Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
Andreani et al. Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
Davies et al. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance
Kawaguchi et al. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
Xiao et al. Anillin facilitates cell proliferation and induces tumor growth of hepatocellular carcinoma via miR-138/SOX4 axis regulation
Sun et al. miR-101-3p sensitizes hepatocellular carcinoma cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy
Li et al. Piwi-interacting RNA1037 enhances chemoresistance and motility in human oral squamous cell carcinoma cells
EP2649451A1 (en) Agtr1 as a marker for bevacizumab combination therapies

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20180313